BiotechTube
MetaCurUm Biotech

MetaCurUm Biotech

Stockholm, Sweden· Est.
metacurum.se
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

MetaCurUm Biotech is a preclinical-stage company developing a first-in-class antibody targeting a specific oncogenic TGFβ pathway to inhibit metastasis, addressing a critical unmet need in aggressive cancers. Its lead indication is metastatic castration-resistant prostate cancer, with a pipeline intended for breast, lung, kidney, and endometrial cancers. The company, a Umeå University spin-off, is backed by non-dilutive Swedish innovation grants (Vinnova) and is led by a team with deep drug development and scientific expertise. Its strategy combines a novel therapeutic mechanism with a precision medicine approach through parallel biomarker development.

Oncology

Technology Platform

Monoclonal antibody targeting a unique oncogenic TGFβ signaling pathway to prevent cancer metastasis, coupled with a companion biomarker development program.

Opportunities

The company addresses the massive unmet need in preventing cancer metastasis, the cause of 90% of cancer deaths, starting with the large mCRPC market.
Its unique TGFβ mechanism and parallel biomarker program position it for a precision medicine approach, potentially enabling partnerships.
The platform offers expansion potential into other major cancer indications (breast, lung) and even non-oncology TGFβ-related diseases.

Risk Factors

High preclinical risk: the novel TGFβ mechanism must be validated and show a safe therapeutic window, a historical challenge for this target class.
The company is financially vulnerable, reliant on grants and needing to raise significant venture capital to advance.
It operates in the highly competitive prostate cancer and TGFβ inhibitor landscapes against larger, better-funded entities.

Competitive Landscape

MetaCurUm competes in the challenging TGFβ inhibitor space, which includes companies like Scholar Rock (focusing on latent TGFβ activation) and numerous large pharma programs that have faced toxicity hurdles. In prostate cancer, it will ultimately compete with entrenched AR-targeted therapies, chemotherapies, radiopharmaceuticals, and novel immunotherapies. Its differentiation lies in its specific anti-metastatic mechanism and biomarker strategy.

More companies in Sweden →